



Rosa Herrera  
Fleishman Hillard  
404.739.0153  
[herrerar@fleishman.com](mailto:herrerar@fleishman.com)

**FOR IMMEDIATE RELEASE**

### **ALIMERA SCIENCES FUNDING EARNS “DEAL OF THE YEAR”**

ATLANTA (January 26, 2005) — Alimera Sciences Inc., an emerging ophthalmic pharmaceutical company, announced that the company was awarded the Georgia Biomedical Partnership (GBP) inaugural Deal of the Year award for its 2004 Series A financing of \$26.75 million.

The Deal of the Year award recognizes transactions, such as financing and partnering agreements, that significantly impact the development of Georgia’s life sciences industry. According to GBP, Alimera Sciences’ Series A funding deal was one of the largest initial venture capital investments in a Southeast life sciences community during the past 10 years.

“Alimera Sciences is honored to be recognized by GBP and proud to be a part of the Georgia life sciences community,” said Dan Myers, CEO of Alimera Sciences. “The company’s Series A funding provided us the opportunity to continue developing and acquiring new treatments that address underserved areas in the ophthalmology market.”

Since its Series A funding, Alimera Sciences has launched and began to market *Soothe*<sup>™</sup> Emollient (Lubricant) Eye Drops, the market’s first multi-dose, emollient-based artificial tear product. This year, Alimera will initiate development of its prescription pipeline and expand distribution for its over-the-counter product.

Inhibitex, a publicly traded biopharmaceutical company, also received a GBP Deal of the Year award.

#### **About Alimera Sciences Inc.**

Alimera Sciences Inc. specializes in the development and commercialization of over-the-counter and prescription ophthalmology pharmaceuticals. Founded by an executive team with extensive development and revenue growth expertise, Alimera Sciences’ products address underserved and overlooked areas of the ophthalmic market. In August 2004, Alimera Sciences unveiled *Soothe*<sup>™</sup>, the market’s first multi-dose, emollient-based artificial tear product.

[www.alimerasciences.com](http://www.alimerasciences.com)

###